AEON Biopharma Appoints New CMO, Director

TL;DR

AEON Biopharma beefs up leadership with a new CMO and board member.

AI Summary

AEON Biopharma, Inc. announced on May 16, 2024, the appointment of Dr. Robert L. Ferris as Chief Medical Officer and the election of Ms. Sarah E. Empey to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, though specific dollar amounts were not detailed in this filing.

Why It Matters

The appointment of a new Chief Medical Officer and a Board Director signals potential strategic shifts and leadership changes within AEON Biopharma, which could impact its drug development and business strategy.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may affect future company performance and strategy.

Key Players & Entities

• AEON Biopharma, Inc. (company) — Registrant
• Dr. Robert L. Ferris (person) — Appointed Chief Medical Officer
• Ms. Sarah E. Empey (person) — Elected to Board of Directors
• May 16, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri

Filing Documents

• aeon-20240516x8k.htm (8-K) — 40KB
• 0001837607-24-000066.txt ( ) — 170KB
• aeon-20240516.xsd (EX-101.SCH) — 4KB
• aeon-20240516_def.xml (EX-101.DEF) — 3KB
• aeon-20240516_lab.xml (EX-101.LAB) — 17KB
• aeon-20240516_pre.xml (EX-101.PRE) — 10KB
• aeon-20240516x8k_htm.xml (XML) — 5KB

02. Resignation of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Item 5.02. Resignation of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. (b) On May 16, 2024, AEON Biopharma, Inc. ("AEON" or the "Company") terminated the Consulting Agreement (the "Agreement") between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024. (c) Appointment of Principal Financial Officer On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024. Mr. Forth is our President, Chief Executive Officer and a member of the Board. Mr. Forth has served as the President and Chief Executive Officer of AEON since December 2019 and was Chief Executive Officer of ABP Sub Inc., Old AEON's wholly owned subsidiary prior to the Subsidiary Merger, also starting in May 2019. Prior to that time, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Division. Mr. Forth was responsible for all aspects of the commercialization of both current and future products within Neurosciences, Urology and Medical Dermatology, most notably Botox for all therapeutic uses from February 2014 to May 2019. Mr. Forth has held various leadership roles within Allergan since June 2003, including Vice President, Sales and Marketing Urology from February 2011 to February 2014 and Vice President, Specialty Therapeutics from July 2008 to February 2011. From June 2003 to July 2008, Mr. Forth also worked in various roles of increasing responsibility most notably focused on U.S. Aesthetics (Botox Cosmetic) and Global Strategic Marketing (Botox Therapeutic). Prior to Allergan, Mr. Forth held various Sales and Marketing roles of increasing responsibility at TAP Pharmaceutical Inc., a specialty company focused on Urology, Oncology, Gynecology and Gastroentero

01. Other Events

Item 8.01. Other Events AEON has delivered notice to PPD, Inc., the Company's clinical research organization, to discontinue the Company's Phase 2 double blind study of ABP-450 in the treatment of migraine (the "Migraine Study"), which had previously completed enrollment and dosing of patients, and to cease enrollment and dosing of patients in the Company's open label extension study related to the Migraine Study (the "OLE Study"). Patients in the Migraine Study and OLE Study will be monitored for safety purposes through the 12-week period following their last treatment. The Company previously announced, in October 2023, topline data from the episodic migraine cohort of the Migraine Study, which failed to achieve its primary endpoint but did achieve certain key secondary endpoints and, in May 2024, interim topline data from the chronic migraine cohort of the Migraine Study, which failed to achieve its primary and secondary endpoints. The termination of the Migraine Study and OLE Study will allow the Company to conserve cash while it evaluates its strategic options. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: May 16, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR